Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 5/20 | 0.32 |
| ▸ | HNF4A | P41235 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281171 | 0.67 | RXRA (0.43) | RXRAHNF4ARXRBRXRG | |
| SCHEMBL8005483 | 0.65 | RXRA (0.50) | RXRAHNF4ARXRBRXRG | |
| SCHEMBL6281394 | 0.64 | CNR2 (0.34) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5364822 | 0.63 | RXRA (0.48) | RXRAHNF4ARXRBRXRG | |
| SCHEMBL5846268 | 0.63 | RXRA (0.36) | RXRAHNF4A | |
| SCHEMBL6033082 | 0.63 | RXRA (0.43) | RXRAHNF4ARXRBRXRG | |
| SCHEMBL27823623 | 0.63 | CNR2 (0.43) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6033474 | 0.62 | RXRA (0.32) | RXRAHNF4A | |
| SCHEMBL6033311 | 0.61 | RARA (0.46) | RXRAHNF4ARXRBRXRG | |
| SCHEMBL27802861 | 0.61 | NPC1 (0.45) | CNR2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096380-A1 | 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6887896-B1 | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096380-A1 | 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | TPO, THRA, FABP6 | CNR2 2741/4885PDE4A 2260/4885PDE4B 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.